9 June 2021
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 ("MAR") AND THE RETAINED UK LAW VERSION OF MAR PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019 (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN INDUCTION HEALTHCARE GROUP PLC IN ANY JURISDICTION.
THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES OF AMERICA. THE SECURITIES DISCUSSED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OF AMERICA ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT.
Induction Healthcare Group PLC
(“Induction”, the “Company”, or the “Group”)
Completion of Acquisition of Attend Anywhere
Induction (AIM: INHC), a leading virtual care platform driving digital transformation of healthcare systems worldwide, is pleased to announce that it has today completed the acquisition of Attend Anywhere Pty Ltd (“Attend Anywhere”) (the “Acquisition”). The cash consideration of approximately £16.35 million includes approximately £0.79 million as payment for Attend Anywhere’s net assets at completion.
In addition, the 14,285,714 new ordinary shares to be issued as consideration pursuant to the Acquisition will be admitted to trading on AIM at 8.00 a.m. on 10 June 2021. Following this, the Company’s issued share capital will comprise of 92,050,727 ordinary shares and the total number of voting rights in the Company will be 92,050,727. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
James Balmain, Induction Joint CEO, said: “We are delighted to complete the acquisition of Attend Anywhere which is the latest development in our journey to provide a comprehensive virtual care platform for hospitals, doctors and patients. Attend Anywhere extends our existing product set with a mature video consultation platform already being widely used by NHS hospitals across the UK. Critically, it will also deliver Attend Anywhere customers an even higher standard of user support, technical resilience and customer service, via our existing UK based infrastructure.“Induction products will cover not only pre-treatment patient support (including digital correspondence, appointment booking and remote triage) but also the full range of in-person, telephone and live-video consultations. This will help our NHS hospital customers provide maximum flexibility when addressing the daunting challenge of current secondary care waiting lists. We are very excited about our combined offering and the opportunity we have to make life easier for clinical teams and patients by supporting the NHS’s ongoing digital transformation initiatives.”
Hugo Stephenson, Induction Joint CEO, added:“I am delighted to welcome Attend Anywhere CEO Chris Ryan and his team to be part of the exciting future for Induction as we work together to create an all-encompassing virtual care platform that can be used at scale so that our healthcare systems can work better. Coming together provides us with a strong market position in a significant area of growth and investment. It also gives the enlarged Group good forward visibility, with £9.5m in contracted revenue for our current financial year ending March 2022. “We are very pleased with the support from existing and new investors and we look forward to updating shareholders as we deliver on our integration plan and growth strategy. We are particularly excited about taking a UK platform, used at scale, and exploring its potential in new markets that look to the UK as a digital exemplar, and face similar challenges dealing with long waiting lists and limited space for seeing patients as healthcare systems try to open up after vaccination roll-outs.”
Chris Ryan, Attend Anywhere CEO said:
“The Attend Anywhere model for mainstream, business-as-usual video consultations for health services has been proven at scale. We see a great many synergies with the Induction team, its ethos, products and services. This includes accelerating the development of integrated solutions and services that underpin modern health care delivery, and expanding our operational capabilities and footprint in the UK and in Europe as well as Australia, Asia and elsewhere.”
ENQUIRIESInductionDr Hugo Stephenson, Joint Chief Executive Officer James Balmain, Joint Chief Executive OfficerN+1 Singer (Nominated Adviser and Broker) Philip Davies / Kailey AliyarWalbrook PR LtdPaul McManus / Alice WoodingsAbout Induction - https://inductionhealthcare.com
-ENDS-Via Walbrook PR Ltd:
induction@walbrookpr.com+44 (0) 20 7496 3000 +44 (0)20 7933 8780
Induction (AIM: INHC) is a leading virtual care platform driving digital transformation of healthcare systems worldwide. Induction solutions enhance the investments hospitals have made and lay the foundation for their future. Our products can enable information share between busy doctors, alleviate operational burdens on hospitals or put patients in better control of their care, all while ensuring the highest standards of clinical safety and information security. We unchain staff and patients from the limitations of paper-based and desktop systems, creating massive time and cost efficiencies.More than 225,000 hospital doctors across multiple territories, including the UK, Ireland, Australia and South Africa, as well as a rapidly growing number of more than 250,000 UK patients, choose Induction solutions.Induction Switch is the number one healthcare collaboration app in the UK, used by the majority of hospital doctors within the NHS. The app helps to increase productivity and enhance communication by securely sharing phone numbers and bleeps, bookmarks, documents and messages in a clinical setting.
Induction Guidance provides medical organisations, including most hospital trusts within the NHS, with the ability to collaboratively create, edit, and publish their own local medical guidelines in a secure and locally administrated environment. This increases knowledge of, and adherence to, guidance.Induction Zesty is a market-leading digital platform for patients visiting hospitals. The platform allows patients to book and access their appointments, read their clinical letters, store a copy of their clinical record and provide data to their care teams remotely. It is not just a compelling patient experience, but also delivers significant cost benefits to hospitals.Induction HealthStream is a proprietary data integration platform that reads and writes patient demographic, appointment and clinical record data between a growing number of hospital EHR systems and the Induction platforms. This connectivity between stakeholders and legacy IT systems adds substantial value to pre-existing health IT investment and allows large-scale adoption of Induction app-based services.About Attend Anywhere – https://www.attendanywhere.com/
Attend Anywhere helps hospitals, health systems and other customers offer video consultations to patients and service users as a normal part of day-to-day operations, making it simple, safe and secure to say “yes you can attend your appointment via video”. Since 1998, Attend Anywhere has collaborated with clinicians and patients, medical colleges, universities, healthcare providers, governments, NGAs, and others to bring the benefits of mainstream video call access to health and care systems, with some Attend Anywhere programs now entering their 21st year. The company’s vision is for video consultations to improve lives and help address social, access, equity and sustainability challenges in healthcare and beyond.
IMPORTANT INFORMATION
This Announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or within the United States of America (including its territories and possessions, any State of the United States of America and the District of Columbia), Australia, Canada, New Zealand, the Republic of South Africa, Japan, or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction. This Announcement is for information purposes only and is not intended to and does not contain or constitute or form part of any offer or any solicitation to purchase or subscribe for securities in the United States of America, Australia, Canada, New Zealand, the Republic of South Africa, Japan, or any other state or jurisdiction in which such offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the United States of America, and may not be offered or sold, directly or indirectly, in or into the United States of America except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States of America. No public offer of securities in the United States of America. N+1 Singer, which is authorised and regulated in the United Kingdom by the FCA and is a member of the London Stock Exchange, is acting as nominated adviser to the Company for the purposes of the AIM Rules. N+1 Singer is not acting for any other person in connection with the matters referred to in this document and will not be responsible to anyone other than the Company for providing the protections afforded to clients of N+1 Singer or for giving advice in relation to the matters referred to in this document. N+1 Singer has not authorised the contents of this document for any purpose and, without limiting the statutory rights of any person to whom this document is issued, no representation or warranty, express or implied, is made by N+1 Singer as to any of the contents or the completeness of this document and N+1 Singer does not accept responsibility for this document and accordingly disclaims all and any liability, whether arising in tort, contract or otherwise, which it might otherwise be found to have in respect of this document. Beech Hill is acting as US placing agent to the Company and is not acting for any other person in connection with the matters referred to in this document and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Beech Hill or for giving advice in relation to the matters referred to in this document. Beech Hill has not authorised the contents of this document for any purpose and, without limiting the statutory rights of any person to whom this document is issued, no representation or warranty, express or implied, is made by Beech Hill as to any of the contents or the completeness of this document and Beech Hill does not accept responsibility for this document and accordingly disclaims all and any liability, whether arising in tort, contract or otherwise, which it might otherwise be found to have in respect of this document.
This announcement contains (or may contain) certain forward-looking statements with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, reflect the Directors' beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by any such forward-looking statement. Statements contained in this announcement regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this announcement is subject to change without notice and neither N+1 Singer nor, except as required by applicable law, the Company assumes any responsibility or obligation to update publicly or review any of the forward-looking statements contained herein. You should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement.
Information to Distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the New Ordinary Shares have been subject to a product approval process, which has determined that the New Ordinary Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the New Ordinary Shares may decline and investors could lose all or part of their investment; the New Ordinary Shares offer no guaranteed income and no capital protection; and an investment in the New Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the Target Market Assessment, N+1 Singer will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to New Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the New Ordinary Shares and determining appropriate distribution channels.
